| Title |
Randomized Trial of Perindopril, Enalapril, Losartan and Telmisartan in Overweight or Obese Patients with Hypertension
|
|---|---|
| Published in |
Clinical Drug Investigation, June 2013
|
| DOI | 10.1007/s40261-013-0094-9 |
| Pubmed ID | |
| Authors |
Sergey V. Nedogoda, Alla A. Ledyaeva, Elena V. Chumachok, Vera V. Tsoma, Galina Mazina, Alla S. Salasyuk, Irina N. Barykina |
| Abstract |
Obesity exacerbates hypertension and stimulates the renin-angiotensin-aldosterone system (RAAS). Full-dose RAAS inhibition could be a therapeutic option in overweight or obese patients with hypertension. This study compared four RAAS inhibitors at full therapeutic doses to determine their effect on blood pressure (BP) and cardiovascular risk factors in these patients. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 53 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 15% |
| Student > Bachelor | 8 | 15% |
| Student > Postgraduate | 6 | 11% |
| Student > Master | 6 | 11% |
| Other | 4 | 7% |
| Other | 9 | 17% |
| Unknown | 13 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 28% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 11% |
| Sports and Recreations | 4 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Agricultural and Biological Sciences | 2 | 4% |
| Other | 7 | 13% |
| Unknown | 17 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2016.
All research outputs
#6,929,526
of 22,721,584 outputs
Outputs from Clinical Drug Investigation
#248
of 959 outputs
Outputs of similar age
#59,471
of 196,393 outputs
Outputs of similar age from Clinical Drug Investigation
#1
of 16 outputs
Altmetric has tracked 22,721,584 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 959 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 196,393 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.